Compare CRCT & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | SVRA |
|---|---|---|
| Founded | 1969 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.6M | 1.0B |
| IPO Year | 2021 | 2009 |
| Metric | CRCT | SVRA |
|---|---|---|
| Price | $4.08 | $5.31 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.50 | ★ $7.33 |
| AVG Volume (30 Days) | 600.2K | ★ 1.4M |
| Earning Date | 03-03-2026 | 03-13-2026 |
| Dividend Yield | ★ 23.00% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $708,780,000.00 | N/A |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $0.98 | $430.87 |
| P/E Ratio | $11.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.92 | $1.89 |
| 52 Week High | $7.33 | $7.01 |
| Indicator | CRCT | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 48.76 |
| Support Level | $3.92 | $5.10 |
| Resistance Level | $4.57 | $6.10 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 49.28 | 52.24 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).